Recent Research Analysts’ Ratings Changes for BioMarin Pharmaceutical (BMRN)

A number of research firms have changed their ratings and price targets for BioMarin Pharmaceutical (NASDAQ: BMRN):

• 5/22/2026 – BioMarin Pharmaceutical had its price target lowered by Canaccord Genuity Group Inc. from $116.00 to $111.00. They now have a “buy” rating on the stock.
• 5/19/2026 – BioMarin Pharmaceutical had its price target lowered by Bank of America Corporation from $85.00 to $80.00. They now have a “buy” rating on the stock.
• 5/19/2026 – BioMarin Pharmaceutical is now covered by Citigroup Inc.. They set a “buy” rating and a $75.00 price target on the stock.
• 5/18/2026 – BioMarin Pharmaceutical was upgraded by Citigroup Inc. to “strong-buy”.
• 5/18/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $55.00 to $50.00. They now have a “neutral” rating on the stock.
• 5/15/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/11/2026 – BioMarin Pharmaceutical is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $69.00 price target on the stock.
• 5/7/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $104.00 to $116.00. They now have a “buy” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its price target lowered by Sanford C. Bernstein from $94.00 to $82.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its price target lowered by Morgan Stanley from $120.00 to $119.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $66.00 price target on the stock.
• 5/5/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 5/1/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 4/27/2026 – BioMarin Pharmaceutical is now covered by Morgan Stanley. They set an “overweight” rating and a $120.00 price target on the stock.
• 4/16/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 3/31/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 3/25/2026 – BioMarin Pharmaceutical was upgraded by Truist Financial Corporation to “strong-buy”.

Insiders Place Their Bets

In other news, EVP Charles Greg Guyer sold 16,486 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares in the company, valued at approximately $4,833,958.38. This represents a 17.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 26,093 shares of company stock valued at $1,555,389 over the last quarter. 0.85% of the stock is owned by corporate insiders.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.